NCT01288092 2012-06-07BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast CancerNovartisPhase 2 Withdrawn